Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin

Journal of the American College of Cardiology

Volumn 32, Issue 3, 1998, Pages 665-672

  Brown, Alan S ^a   Bakker Arkema, Rebecca G ^h   Yellen, Laurence ^b   Henley Jr , Robert W ^c   Guthrie, Richard ^d   Campbell, Cam F ^e   Koren, Michael ^f   Woo, William ^g   McLain, Richard ^h   Black, Donald M ^h  

^a Midwest Heart Foundation   (United States)

^b Medical Associates Research Group   (United States)

^c Cardiovascular Associates of Virginia   (United States)

^d St Paul Heart Clinic   (United States)

^e Iowa City Heart Center PC   (United States)

^f Clinic Jacksonville   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COLESTIPOL; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; SIMVASTATIN; TRIACYLGLYCEROL;

ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; CHOLESTEROL, LDL; COLESTIPOL; COMBINED MODALITY THERAPY; DIET, FAT-RESTRICTED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEPTANOIC ACIDS; HUMANS; INDOLES; LOVASTATIN; MALE; PYRROLES; SIMVASTATIN; TREATMENT OUTCOME;

EID: 0031692691     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00300-3     Document Type: Article

References (19)

1. American Heart Association. Heart and Stroke Facts: 1996 Statistical Supplement. Dallas, TX, 1995.
2. Montague T.J., Tsuyuki R.T., Burton J.R., Dzavik V., Williams R., Teo K.K. Prevention and regressions of coronary atherosclerosis Is it safe and efficacious therapy? Chest. 105:1994;718-726.
3. Gotto A.M. Jr, LaRosa C.J., Hunninghake D., et al. The cholesterol facts A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease . Circulation. 81:1990;1721-1733.
4. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
5. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol-lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;334:1383-9.
6. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
7. Furberg C.D., Adams H.P. Jr, Applegate W.B., et al. Effects of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 90:1994;1679-1687.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269(23):3015-23.
9. Nawrocki J.W., Weiss S.R., Davidson M.H., et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 15:1995;678-682.
10. Davidson M.M., McKenney J.M., Stein E.A., et al. Long-term efficacy and safety of atorvastatin compared to lovastatin in hypercholesterolemic patients. Am J Cardiol. 79:1997;1475-1481.
11. Bertolini S., Bon G.B., Campbell L.M., et al. The efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 130:1997;191-197.
12. Remmell P.S., Gorder D.D., Hall Y., Tillotson J.L. Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT), I Use of a dietary monitoring tool . JAMA. 76:1980;351-356.
13. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of a centrifuge. Clin Chem. 22:1972;98-101.
14. Feskanich D., Buzzard I.M., Welch B.T., et al. Comparison of a computerized and manual method of food coding for nutrient intake studies. J Am Diet Assoc. 88:1988;1263-1267.
15. Steiner P.M., Freidel J., Bremner W.F., Stein E.A. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the Lipid Clinics methodology. J Clin Chem Clin Biochem. 19:1981;850.
16. Warnick G.R., Albers J.J. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res. 19:1978;67-76.
17. Lipid and lipoprotein analysis: In: Manual of Laboratory Operations: LRC Program Report (NIH) 75-628. US Department of Health, Education and Welfare, 1974, Vol 1.
18. Albers J.J., Marcovina S.M., Kennedy H. International Federation of Clinical Chemistry Standardization Project for measurement of apolipoproteins A-1 and B-II evaluation and selection of candidate reference materials . Clin Chem. 38:1992;658-662.
19. Schectman G., Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease factors limiting achievement of lipid goals . Am J Med. 100:1996;197-204.